Jinlong Hu, Nan Ge, Sheng Wang, Xiang Liu, Jintao Guo, Guoxin Wang and Siyu Sun
gastrointestinal hemorrhage and abdominal pain. [ 6 ] Many glomus tumors of the stomach, however, are misdiagnosed as other mesenchymal tumors, such as gastrointestinalstromaltumors (GISTs) and leiomyomas. Therefore, it is of paramount importance to accurately preoperative diagnose gastric glomus tumors. Endoscopic ultrasound (EUS) is a useful imaging technique for diagnosing the gastric submucosal tumors, [ 7 , 8 , 9 ] but only a few case reports have been published regarding the characteristics of gastric glomus tumors. [ 10 ]
Surgical resection is a curable treatment
Ayper Kaçar, Hacı Ahmet Demir, Haydar Durak and Sergülen Dervişoğlu
Spindle cell rhabdomyosarcoma is a rare subtype of rhabdomyosarcoma mainly seen in children. Occasional aberrant staining with a variety of immunohistochemical markers has been noted. The aberrantly expressed markers include alpha-smooth muscle actin, cytokeratin, S100, neurofilaments, CD20, immunoglobins, and CD117. We report herein two pediatric cases displaying strong CD34 positivity and one with additional focal CD117 positivity, causing considerable difficulty in distinction from solitary fibrous tumor and extra-gastrointestinal stromal tumor. To our knowledge, CD34 staining has been merely reported in rhabdomyosarcoma. Spindle cell rhabdomyosarcoma has to be considered in the differential diagnosis of childhood spindle cell tumors. Post-chemotherapy specimens should be evaluated in caution, since chemotherapy can cause considerable changes in tumor antigen expression. Since CD117 and CD34 are stem cell markers, their positivity in pediatric tumors should be interpreted with caution. Even if the morphology is not supportive, a wide immunohistochemical panel should be applied in childhood malignant solid tumors
Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. This solid tumor is one of the most challenging diseases to treat for the medical oncologist. STS often forms in the body’s muscles, joints, fat, nerves, deep skin tissues, and blood vessels. The natural history of high-grade STS is characterized by a strong tendency toward local recurrence and metastatic spreading, despite optimal initial strategies. The lung is the most common site of metastases, with poor prognosis. We present the current international guidelines for the adjuvant treatment and systemic treatment for advanced STS and the new discoveries. Many new molecular targeting drugs have been tried in the last ten years, and some were approved for soft tissue sarcoma. The first approved was Imatinib, as a treatment for gastrointestinal stromal tumors (GISTs). Following Imatinib, other tyrosine kinase inhibitors (TKIs) received the approval for GISTs such as Sunitinib and Regorafenib, and Pazopanib for non-GIST soft tissue sarcomas. In 2016, FDA approved the first monoclonal antibody that targets platelet-derived growth factor receptor (PDGFR)-α, Olaratumab. The new treatment demonstrates an overall survival advantage. In this review, we aimed to summarize the results from the most recent studies on adjuvant treatment for high-grade STS and systemic strategies for advanced STS.
Katarzyna Cieszczyk, Iwona Pasnik, Lech Wronecki, Anna Ostrowska, Pawel Bojar, Barbara Marzec-Kotarska and Justyna Szumilo
1. Jeong IH, Maeng YH. Gastric lipomatosis. J Gastric Cancer . 2010; 10:254-8.
2. Xiuli L, Wilcox CM, Nodit L, Lazenby AJ. Multiple gastrointestinalstromaltumors and lipomatosis. Arch Pathol Lab Med. 2008;132: 1825-9.
3. Aoyama S, Ami K, Fukuda A, Imai K, Chong JM, Ando M. Gastric lipomatosis treated by total gastrectomy: a case report. Surgical Case Reports . 2017;3:126.
4. Weinberg T, Feldman M. Lipomas of the gastrointestinal tract. Am J Clin Pathol . 1955;25:272-81.
5. Mills ES. Histology for Pathologists . 4
Sofija Pejkova, Gjorgje Dzokic, Smilja Tudzarova-Gjorgova and Sasho Panov
; 33(1): 33–7.
55. Willmore-Payne C, Layfield LJ, Holden JA. c-KIT mutation analysis for diagnosis of gastrointestinalstromaltumors in fine needle aspiration specimens. Cancer. 2005; 105(3): 165–70.
56. Fukuda R, Hamamoto N, Uchida Y et al. Gastrointestinalstromaltumor with a novel mutation of KIT proto-oncogene. Intern Med. 2001; 40(4): 301–3.
57. Curtin JA, Busam K, Pinkel D et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24(26): 4340–6.
58. Cachia AR, Indsto JO, McLaren KM et al. CDKN2A mutation
Oktay Buyukasik, Ahmet Hasdemir, Yusuf Gulnerman, Cavit Col and Ozgur Ikiz
Tepes B, Kavalar R. Gastric cancer, screening possibilities and proposals for endoscopic and histologic follow-up of premalignant gastric lesions. Zdrav Vest 2010; 79 : 366-74.
Zokalj I, Culinovic-Caic R, Magas Z, Pavcec Z, Saghir H, Igrec J, et al. Gastric gastrointestinalstromaltumour. Radiol Oncol 2008; 42 : 187-95.
Ohtani H, Yashiro M, Onoda N, Nishioka N, Kato Y, Yamamoto S, et al. Synchronous multiple primary gastrointestinal cancer exhibits frequent microsatellite
Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-freerate as the primary endpoint for phase II study in soft tissue sarcoma.European Journal of Cancer 2002;38:543-9.
 Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinalstromaltumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006.
 Sleijfer S